Antiprotozoal medications associated with increased longevity and reduced morbidity in two national cohorts

Running Title: Antiprotozoal medications and longevity

Ariel Israel[1,2]* MD, PhD, Abraham Weizman MD[3], Sarah Israel MD[4], Shai Ashkenazi MD, MSc[5,6], Eytan Ruppin MD, PhD[7], Shlomo Vinker MD, MHA[1], Eli Magen MD[8], Eugene Merzon MD, MPH[1,5]

Affiliations:

[1] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Ramat Aviv, Tel Aviv 6997801, Israel

[2] Leumit Research Institute, Leumit Health Services, 23 Sprinzak St., Tel Aviv 6473817, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Israel

[4] Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, P.O. Box 12000, Jerusalem 9112001, Israel

[5] Adelson School of Medicine, Ariel University, Ariel 40700, Israel

[6] Department of Infectious Diseases, Schneider Children's Medical Center, 14 Kaplan St., Petah Tikva 4920235, Israel

[7] Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[8] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Derech HaRofe 7, Ashdod 7747629, Israel

Corresponding author: Ariel Israel, Leumit Research Institute, Sprinzak 23, Tel-Aviv 6473817, Israel, Telephone: +972-3-6970483. Fax: +972-76-8889190
Email: aisrael@leumit.co.il

Word count: 3754

Tables count: 3

Figures count: 4

Abstract

We conducted a stepwise pharmacoepidemiologic investigation to identify medications associated with longevity and aging-related morbidity. An exploratory medication-wide screen in a large national health system identified two antiprotozoals, atovaquone-proguanil and mefloquine, that were associated with increased survival. Matched exposed-unexposed cohorts were then constructed to validate mortality associations and examine incident outcomes, showing reduced risks for diabetes, dementia, cardiovascular, renal, hepatic, pulmonary, and selected cancers, alongside increased risks for hearing loss, dry eye/Sjögren's, and lichen planus. These findings were externally validated in the US TriNetX network, where the same patterns were observed for atovaquone-proguanil, mefloquine, and nirmatrelvir-ritonavir. Because nirmatrelvir-ritonavir is prescribed to older, multimorbid individuals with COVID-19, its associations are unlikely to reflect healthy traveler bias. The concordant protective and tissue-specific adverse associations across datasets and antiprotozoal drug classes support a testable mechanistic hypothesis: short antiprotozoal courses may mitigate aging-related morbidity, plausibly by reducing protozoal burden, such as *Toxoplasma gondii*.

Keywords: Aging; Longevity; Pharmacoepidemiology; Antiprotozoal agents; *Toxoplasma gondii*; Mortality; Drug repurposing

Introduction

Identifying the long-term effects of medications is a central goal of pharmacoepidemiology and drug repurposing research. Many approved drugs may exert previously unrecognized influences on human health, with potential benefits or harms extending beyond their original indications. Medications that promote healthy aging would be expected to reduce mortality and lower the incidence of chronic disease.

Electronic health records (EHRs) from large healthcare organizations offer a powerful resource for systematically evaluating the long-term effects of medications on mortality and age-related morbidity [1-3]. Using EHR data from Leumit Health Services (LHS), a nationwide provider in Israel, we performed a medication-wide exploratory screen to identify drugs associated with increased longevity. This discovery analysis highlighted two antiprotozoal agents, atovaquone-proguanil and mefloquine, both primarily prescribed for malaria prophylaxis in travelers.

The identification of antiprotozoal medications as longevity-associated agents is consistent with emerging evidence linking the human microbiome to age-related diseases, including cardiovascular [4], metabolic [5], malignant [6] and neurodegenerative disorders [7,8]. Antiprotozoal agents may modulate the microbiome—particularly through elimination of specific protozoal pathogens—and thereby influence long-term health outcomes beyond their original therapeutic purposes.

To explore and validate these findings, we undertook a sequence of follow-up analyses. In LHS, we constructed matched exposed-unexposed cohorts to validate mortality associations and to examine the incidence of common age-related conditions in the decade following the first uptake of antiprotozoal medications. We then sought external validation in the US-based TriNetX federated network, comprising EHR data from more than 120 million individuals. There, we examined atovaquone-proguanil and mefloquine, prescribed mainly for malaria prophylaxis in travelers, alongside nirmatrelvir-ritonavir, an antiviral used in older and comorbid patients at risk for COVID-19

complications that also has antiprotozoal activity. Inclusion of this latter cohort helped address potential "healthy traveler" bias by confirming that protective associations extend to non-traveler populations. Across these analyses, we observed consistent associations between antiprotozoal exposure and reduced mortality, accompanied by concordant changes in the incidence of multiple age-related diseases.

Figure 1 summarizes the study design, which comprised three sequential analyses: a discovery screen in LHS (Analysis A), a validation-exploration cohort in LHS (Analysis B), and external validation in TriNetX (Analysis C).

Results

Analysis A: LHS exploratory cohort

Table 1 summarizes the demographic and clinical characteristics of 14,986 patients who died before the cohort median age of death (cases) and 14,986 matched survivors (controls) in the LHS cohort. Matching ensured similar distributions of age, sex, and socioeconomic status (49.2% female, mean age 71.0 ± 5.9 years at index). Compared to controls, cases had slightly higher BMI (29.1 ± 6.0 vs. 28.5 ± 4.8 kg/m²) and weight (77.5 ± 17.7 vs. 76.3 ± 14.6 kg) and were more likely to be smokers (OR 2.00, 95% CI 1.86-2.15). After an average follow-up of 12.5 years, controls reached a mean age of 83.6 ± 5.9 years, while cases died at a mean age of 74.3 ± 5.7 years (Table 1B).

Analysis A results: Medications associated with decreased mortality

Medication use during the preceding decade was systematically evaluated for associations with mortality. Supplementary Table 1 lists the two compounds that met the false discovery rate (FDR <5%, Benjamini-Hochberg correction). Both were antiprotozoal agents and were significantly associated with reduced mortality: mefloquine (OR 0.32, 95% CI 0.15-0.65, FDR = 0.0001) and atovaquone-proguanil (OR 0.43, 95% CI 0.27-0.69, FDR = 0.0002).

Analysis B: Validation-Exploration Cohort in LHS

These findings prompted a more detailed evaluation of mortality and morbidity outcomes in matched cohorts. We constructed a cohort of individuals aged 40-85 who had received at least one prescription for either A-P or mefloquine, and matched each treated patient to 20 unexposed controls based on sex, socioeconomic status (SES), and year of first LHS membership. The final cohort included 3,876 treated individuals and 77,820 controls with broadly comparable baseline characteristics (Table 2).

The mean age was 56.3 years in both groups, with 52.3% female participants. Small but statistically significant baseline differences were noted for BMI (27.0 ± 4.5 vs. 27.5 ± 5.2 kg/m², $p < 0.001$), weight (76.3 ± 15.3 vs. 77.3 ± 16.5 kg, $p < 0.001$), and height (168 ± 9 vs. 167 ± 10 cm, $p < 0.001$). Systolic blood pressure was similar across groups, while diastolic blood pressure was slightly lower among treated individuals (76.8 ± 10.1 vs. 77.5 ± 9.0 mmHg, $p < 0.001$). Current smoking was significantly less frequent in the treated group (14.5% vs. 21.8%, $p < 0.001$), although past smoking rates and ethnic group distributions were similar between cases and controls.

Analysis B: Cox proportional hazards models

We next evaluated the association between exposure to A-P or mefloquine and subsequent mortality and morbidity using Cox proportional hazards models (cumulative incidence plots in Figure 2). Treated individuals had markedly reduced risk of all-cause mortality (HR = 0.40 [95% CI, 0.34-0.47], $p < 10^{-200}$; Figure 2A). Significant reductions were also observed for dementia (HR = 0.52 [0.41-0.67], $p < 10^{-6}$; Figure 2B), diabetes mellitus (HR = 0.83 [0.75-0.92], p = 0.0006; Figure 2C), heart failure (HR = 0.76 [0.63-0.91], p = 0.006; Figure 2D), myocardial infarction (HR = 0.78 [0.66-0.92], p = 0.003; Figure 2E), hepatic failure (HR = 0.64 [0.43-0.95], p = 0.03; Figure 2F), chronic obstructive pulmonary disease (COPD) (HR = 0.73 [0.62-0.86], p = 0.0002; Figure 2G), gastrointestinal malignancy (HR = 0.70 [0.52-0.96], p = 0.03; Figure 2H), and lung cancer (HR = 0.52 [0.33-0.82], p = 0.004; Figure 2I).

Conversely, treated individuals exhibited significantly increased risks of hearing loss (HR = 1.25 [1.14-1.37], $p < 10^{-5}$; Figure 2J), Sjögren's disease/eye dryness (HR = 1.25 [1.14-1.38], $p < 10^{-5}$; Figure 2K), and lichen planus (HR = 1.54 [1.03-2.31], p = 0.03; Figure 2L).

A forest plot summarizing these outcomes (Figure 3) illustrates the broad reductions in mortality and major age-related conditions associated with antiprotozoal exposure, alongside increased risks of specific auditory, ophthalmic, and dermatologic conditions.

Analysis C: Validation cohorts in the US-based TrinetX collaborative network.

To validate the associations observed in the LHS national cohort, we conducted independent analyses in TriNetX, a federated network comprising EHRs from over 69 US healthcare organizations and more than 120 million patients. Within this population, we defined matched cohorts for exposure to A-P and mefloquine, focusing on individuals currently aged 70-89. Cases were defined as those with a record of the medication of interest, while controls had no such exposure. Propensity score matching (PSM) was applied to balance groups on age, sex, race, ethnicity, smoking status, diabetes, BMI, and HbA1c at baseline.

To address potential indication bias stemming from the use of antimalarials primarily in travelers, we included a third validation cohort exposed to nirmatrelvir-ritonavir (N-R, Paxlovid). This drug was selected because of its predicted antiprotozoal properties and its widespread prescription as an antiviral during the COVID-19 pandemic. The N-R cohort offered substantially greater statistical power than the smaller A-P and mefloquine cohorts; however, follow-up was limited to a maximum of three years given the recent introduction of this medication, in contrast to the longer observation periods available for A-P and mefloquine.

The final matched cohorts included 24,498 exposed individuals and 24,498 controls for A-P, 3,400 exposed and 3,400 controls for mefloquine, and 124,681 exposed and 124,681 controls for N-R (Table 3). Across cohorts, mean age at index was closely matched (69.0 ± 5.8 years for A-P, 67.6 ± 6.2

years for mefloquine, and 75.0 ± 5.5 years for N-R). Sex distributions were balanced (55% female for A-P, 52% for mefloquine, 58% for N-R). Race and ethnicity distributions were similar within each matched cohort, with the majority identified as White (83% for A-P, 56% for mefloquine, 85% for N-R). Baseline prevalence of nicotine dependence (3-8%), diabetes mellitus (14-26%), and overweight/obesity (13-27%) were comparable between groups. HbA1c and BMI were also closely matched, ensuring well-balanced baseline metabolic profiles for subsequent outcome analyses.

Analysis C: Cox proportional hazard models

In the TriNetX cohorts, we evaluated mortality and age-related conditions identified in the LHS analyses, excluding individuals with a prior diagnosis of each outcome at baseline. Cumulative incidence plots are presented in Figure 4.

Consistent and significant reductions in all-cause mortality were observed across all three medications: HR = 0.26 (95% CI, 0.24-0.28; $p < 10^{-3}$) for A-P, HR = 0.33 (0.27-0.40; $p < 10^{-3}$) for mefloquine, and HR = 0.50 (0.48-0.52; $p < 10^{-3}$) for N-R. Significant reductions were found for major chronic diseases. Dementia incidence was reduced (HR = 0.48-0.64 across medications), as were diabetes mellitus diagnoses (HR = 0.56-0.75) and diabetes defined by first occurrence of HbA1c ≥ 6.5% (HR = 0.57-0.68). Kidney disease, defined as an eGFR < 45 mL/min/1.73 m^2, was also significantly reduced (HR = 0.53-0.71). Additional reductions were observed for heart failure (HR = 0.55-0.75), myocardial infarction (HR = 0.55-0.89), hepatic failure (HR = 0.28-0.48), COPD (HR = 0.45-0.69), lung cancer (HR = 0.47-0.69), gastrointestinal malignancies (HR = 0.56-0.70), and brain malignancies (HR = 0.63 for A-P and N-R). All results reached statistical significance ($p < 0.05$, most $< 10^{-}$).

As in the LHS cohort, antiprotozoal exposure was associated with higher risks of specific adverse outcomes, including hearing loss (HR = 1.53-1.65), Sjögren's syndrome/dry eye (HR = 1.50-2.11), retinal detachment (HR = 1.34-2.01 for A-P and N-R), and lichen planus (HR = 1.59-1.73 for A-P and N-R).

Taken together, these findings from independent, large-scale cohorts reinforce the association of antiprotozoal exposure with broad reductions in age-related morbidity and mortality, while consistently highlighting increased risks for specific auditory, ophthalmic, and dermatologic conditions.

Discussion

In this study, we leveraged comprehensive electronic health records from large-scale healthcare networks in two countries to systematically screen for medications associated with increased human lifespan. Using a medication-wide association approach in a national Israeli cohort, we identified two antiprotozoal agents, A-P and mefloquine, as strongly and significantly associated with reduced all-cause mortality and a broad spectrum of age-related morbidities. These findings were independently validated in the U.S.-based TriNetX network, where consistent reductions in mortality and major age-related outcomes were observed for these medications, as well as for N-R—a medication widely used during the COVID-19 pandemic that contains ritonavir, which has known antiprotozoal activity.

The novelty of this work lies in its design: by systematically comparing medication histories over a decade in individuals with above- versus below-average longevity within a large population, we identified a class of medications—antiprotozoals—that consistently exhibit associations with increased lifespan and a reduced incidence of common life-shortening conditions, including diabetes and its complications, cardiovascular and cerebrovascular diseases, chronic kidney disease, hepatic failure, chronic obstructive pulmonary disease, dementia, and various malignancies. Replicating these associations across two independent healthcare systems in different countries, and for three mechanistically related but distinct medications, provides convergent evidence for the robustness of these findings.

These results raise the possibility that many age-related conditions with incompletely understood etiologies may, at least in part, be driven by unrecognized, chronic protozoal colonization, which may represent a ubiquitous and overlooked contributor to chronic inflammation, immune dysregulation, and

tissue damage underlying the biology of aging. Reduction of protozoal load through short-course antiprotozoal therapy may confer long-term health benefits, as observed in both cohorts.

Remarkably, we also observed consistent increases in the incidence of certain adverse outcomes, including hearing loss, Sjögren's syndrome[9], and lichen planus[10], following antiprotozoal exposure. Rather than undermining the protective associations, these findings provide key mechanistic insights and further strengthen the plausibility of our results. These conditions affect cell types and tissues that are highly sensitive to localized immune-mediated damage, which may arise following the pharmacological elimination of intracellular pathogens. The abrupt clearance of these pathogens could trigger localized inflammation and immune activation at sites of prior intracellular colonization, revealing the pathogen reservoirs while concurrently reducing systemic inflammation.

A key question is which pathogen's elimination could underlie these associations. Based on global seroprevalence, tissue tropism, and epidemiological links to neurodegenerative and cardiovascular diseases, we hypothesize that *Toxoplasma gondii* is a likely culprit. As an intracellular parasite, *T. gondii* can colonize the gut, disseminate hematogenously, establish low-grade infections in various tissues, including in the CNS, often evading immune detection. Its presence has been associated with increased risks of dementia[11], schizophrenia[12], and cardiovascular diseases[13], while our findings of reduced diabetes and its complications following antiprotozoal treatment align with the hypothesis that eradication of chronic *T. gondii* infection may mitigate systemic inflammation and thromboembolic risks.

From an evolutionary perspective, it is plausible that *T. gondii* would have developed multiple mechanisms to weaken and accelerate the senescence of its intermediate hosts, thereby increasing the likelihood that they fall prey to felines, its definitive hosts where sexual replication occurs. *T. gondii* has been shown to use sophisticated strategies to hijack neuronal pathways in rodents, diminishing fear responses and facilitating predation by cats [14,15]. In this context, it is likely that the parasite has also

evolved strategies that reduce physical fitness and impair systems essential for long-term survival—such as metabolic, cardiovascular, renal, and hepatic systems—thereby further increasing the chances that fully grown intermediate hosts are captured by feline predators. Such weakening would enhance the parasite's transmission opportunities, aligning with its evolutionary strategy. Humans, as accidental hosts, may suffer the same harms, and *T. gondii* may contribute to aging-related morbidity and mortality, as unintended consequences of its adaptive strategy in natural hosts.

T. gondii is ubiquitous in human environments, with global seroprevalence estimates ranging from 20% to 80% depending on geography and age. The longer individuals live, the greater their cumulative likelihood of environmental exposure and eventual parasitic colonization, even in the absence of overt clinical disease. As an intracellular parasite, *T. gondii* initially colonizes the gastrointestinal tract, where it may induce chronic low-grade inflammation and promote local immune evasion. By interfering with host cell apoptosis and modulating immune surveillance, *T. gondii* may increase the risk of malignancy. Supporting this, we have shown in a recent study that *T. gondii* DNA signatures are enriched in the stool of individuals with colorectal cancer, indicating active or latent gut colonization in these patients [16].

Additionally, *T. gondii* has been reported to colonize the skin[17], which is anatomically contiguous with the gastrointestinal outlet. While evidence is limited, localized colonization of the skin or mucous membranes occurring more broadly, particularly in aging individuals with declining immune surveillance may contribute to chronic, non-specific inflammation and insulin resistance, a hallmark of diabetes mellitus—a condition we found to be reduced following antiprotozoal treatment. Notably, *T. gondii* infections that remain localized without systemic dissemination may not trigger detectable serological responses, consistent with the parasite’s intracellular lifestyle and immune evasion strategies. Supporting this hypothesis, several studies have reported increased *T. gondii* seroprevalence among individuals with diabetes mellitus [18,19].

Furthermore, *T. gondii* is capable of systemic dissemination via hematogenous spread, allowing it to reach and infect a wide range of cell types, notably neuronal tissue within the central nervous system (CNS). Increased seropositivity for *T. gondii* has been associated with a range of neuropsychiatric and neurodegenerative conditions, including dementia and schizophrenia, aligning with our observation of reduced dementia incidence following antiprotozoal treatment [20-25].

Parasite dissemination into the systemic circulation may precipitate thromboembolic phenomena, a proposed mechanism for the association of *T. gondii* with cardiovascular and cerebrovascular morbidity [13,26]. The marked reductions in myocardial infarction and stroke observed following antiprotozoal treatment in our study are consistent with this hypothesis, suggesting that protozoal eradication may mitigate thromboembolic risk by reducing systemic parasite burden and associated vascular inflammation.

Supporting evidence that A-P, mefloquine, and N-R (Paxlovid) possess anti-*Toxoplasma* activity further strengthens the plausibility of our hypothesis.

Atovaquone is a well-established anti-*Toxoplasma* agent that inhibits the parasite's mitochondrial electron transport chain, impairing its energy production and replication. It is used in combination therapies for toxoplasmosis treatment and prophylaxis, with demonstrated efficacy in suppressing and clearing *T. gondii* infections, including in immunocompromised patients. Proguanil, while primarily targeting *Plasmodium*, may enhance atovaquone's efficacy by additional mitochondrial inhibition and by inhibiting dihydrofolate reductase (DHFR), thereby interfering with folate metabolism, which is also required for *T. gondii* survival and replication.[27,28]

Mefloquine is an antiprotozoal widely used for malaria prophylaxis and treatment, particularly against *Plasmodium falciparum* strains resistant to chloroquine and other first-line antimalarials. Importantly, mefloquine has demonstrated both in vitro and in vivo activity against *T. gondii*[29,30]. Animal studies have shown reduced parasite loads and extended survival in infected mice treated with

mefloquine, indicating its ability to target *T. gondii* tissue cysts and tachyzoites through interference with parasite autophagy and disruption of membrane stability. Additionally, mefloquine is thought to impair parasite autophagic pathways and mitochondrial function, further contributing to its efficacy against intracellular protozoa, including *T. gondii*.

Lastly, N-R (Paxlovid) has not been formally studied for *T. gondii* activity; however, ritonavir and related HIV protease inhibitors have demonstrated *in vitro* anti-*Toxoplasma* activity, likely by interfering with the parasite's protease systems and replication cycles[31,32]. Furthermore, protease inhibitors have been investigated for synergistic effects with other anti-*Toxoplasma* agents, supporting their potential role in suppressing *T. gondii* replication.

Medications used for malarial prophylaxis are typically administered for the duration of travel (generally several weeks). Combined with their high intracellular penetration, this treatment period may be sufficient to eliminate or clear a substantial portion of the *T. gondii* burden in the host. By reducing parasite load below a critical threshold, such treatments could enable the immune system to prevent the re-expansion of subclinical foci. This mechanism may underlie the durable reductions in chronic inflammation and the lowered risk of age-related diseases that we observed in both populations, persisting for up to a decade after exposure.

In contrast, N-R is administered for only five days to prevent COVID-19 complications—a much shorter course than typical antimalarial regimens—which may limit its effectiveness in eradicating *T. gondii*. Nevertheless, despite this shorter exposure, we observed similar reductions in all-cause mortality and age-related morbidities, along with increased risks of the same auditory, visual, and dermatologic conditions seen with A-P and mefloquine.

The observed associations of antiprotozoal treatment with hearing loss, retinal detachment, Sjögren's syndrome, and lichen planus further support the biological plausibility of *T. gondii* involvement. These outcomes align with the parasite's known tissue tropism: congenital toxoplasmosis

is a leading cause of sensorineural hearing loss in infants [33], and seropositivity has been linked to hearing impairment [34]; toxoplasma retinitis is the most common cause of posterior uveitis worldwide [35]; and cutaneous toxoplasmosis frequently occurs in immunocompromised individuals [17]. Taken together, these findings suggest that the observed increases in localized conditions after antiprotozoal therapy may reflect parasite clearance from its canonical reservoirs, triggering tissue-specific pathology while simultaneously lowering the risk of systemic spread.

Until now, the prevailing view has been that *Toxoplasma gondii* is largely innocuous in immunocompetent humans, aside from its teratogenic effects in newly infected pregnant women and its impact on immunocompromised individuals. Consequently, serological testing is rarely performed outside these contexts. In histopathological examinations, the small, easily overlooked cysts characteristic of *T. gondii* are typically disregarded or unreported due to the absence of a recognized clinical correlation. This likely contributes to the underrecognition of its potential long-term harms and to the absence of therapeutic strategies aimed at parasite clearance in the general population.

Based on the epidemiologic observations of this study, we hypothesize that chronic *T. gondii* colonization may contribute to aging-related conditions, thereby explaining the association of antiprotozoal therapies with reduced mortality and morbidity. Our findings suggest that even short courses of antiprotozoal treatment may confer long-term benefits, likely by lowering the burden of *T. gondii*. These results underscore the need for further research to determine the prevalence of *T. gondii* infection in aging-related diseases and to assess the potential of targeted clearance strategies—ideally designed to minimize collateral tissue damage—as a means to mitigate age-associated morbidity and mortality.

Limitations

Despite the strengths of our large-scale, systematically matched analyses and replication across independent populations, this study has several limitations. First, as an observational study, residual

confounding cannot be rigorously excluded. However, the consistent observation of both protective and adverse associations (e.g., hearing loss, Sjögren's disease, lichen planus) across large cohorts from different countries, for two distinct antimalarials, and in TriNetX also for N-R—a medication administered during COVID-19 primarily to older and less healthy patients and provided at no cost across socioeconomic groups—argues strongly against selection or indication bias as the main explanation.

Second, in the LHS exploratory analysis (Analysis A), individuals exposed to antimalarials did exhibit slightly healthier baseline characteristics, which may explain part, though not all, of the observed risk reduction. In this design, survival status was used to define cases and controls, reflecting its role as an exploratory, hypothesis-generating screen rather than a causal inference framework. While it could in principle amplify baseline differences between groups, these concerns were addressed in Analyses B and C, where group assignment was based directly on first medication exposure (defining the index date) and outcomes were analyzed longitudinally using survival models. In particular, Analysis C further minimized bias through propensity-score matching, which ensured rigorous baseline balance across demographic and clinical factors, including ethnicity, BMI, diabetes status, HbA1c, and smoking status.

Finally, while the magnitude of the protective associations observed is striking, their replication across two independent healthcare systems strongly suggests that these are not artifacts of study design but reflect genuine biological signals. The persistence of these associations for up to a decade after exposure, and across outcomes that often occur in otherwise healthy individuals (such as malignancy and myocardial infarction), further reduces the likelihood of confounding as the primary explanation. Moreover, the consistent increase in specific adverse outcomes (hearing loss, Sjögren's disease, lichen planus) across all three medications, observed in parallel with reduced mortality and morbidity, supports the conclusion that these patterns represent true drug-related effects rather than spurious associations.

Nonetheless, prospective and mechanistic studies will be essential to confirm causality and to elucidate the underlying biological mechanisms.

Conclusion

Overall, the observed protective effects of antiprotozoal medications against mortality and a broad range of aging-associated diseases—together with consistent increases in conditions linked to canonical reservoirs of *Toxoplasma gondii*—consistent across two countries and three drugs with distinct indications, support the hypothesis that chronic protozoal colonization, most likely *T. gondii*, is an underrecognized contributor to age-related morbidity. The spectrum of affected outcomes, spanning metabolic, cardiovascular, cerebrovascular, neurodegenerative, and malignant diseases, highlights the potential public health significance of this finding. These results raise the possibility that targeted eradication or suppression of protozoal infections could represent a novel strategy to reduce age-related disease burden and lower mortality. Prospective, mechanistic, and interventional studies will be essential to confirm causality and evaluate therapeutic potential.

Methods

Study design

This research was performed in three sequential stages, as illustrated in Figure 1. Each stage was designed to build upon the previous one:

- **Analysis A (Screening stage):** A systematic, medication-wide association analysis in a national Israeli cohort to identify candidate medications associated with longevity.
- **Analysis B (Validation-Exploration stage):** A matched cohort study within LHS focused on the candidate antiprotozoal medications identified in Analysis A, aimed at validating associations with mortality and exploring morbidity outcomes.

- **Analysis C (Replication stage):** Independent validation in the U.S.-based TriNetX research network, including both the candidate antiprotozoals and nirmatrelvir-ritonavir (N-R), selected as an additional comparator with predicted antiprotozoal properties.

Analysis A: LHS Cohort to Identify Drugs Associated with Increased Longevity

The first stage of this research was conducted as a retrospective cohort study within Leumit Health Services (LHS), one of four nationwide health providers in Israel, delivering comprehensive healthcare to approximately 730,000 members. All Israeli citizens are entitled to comprehensive health insurance and receive a standardized package of healthcare services and medications, as defined by the national "Health Basket" committee. LHS operates a centralized electronic health record (EHR) system, maintaining over two decades of meticulously curated data, including patient demographics, medical diagnoses, healthcare encounters, laboratory test results, and records of prescribed medications. In addition, LHS maintains a comprehensive network of affiliated pharmacies, enabling reliable tracking of medication purchases by its members—including over-the-counter medications—which allows for the identification of associations between medication uptake and clinical outcomes.

Cohort eligibility included current and former LHS members with electronic records of medical visits occurring after the age of 60. Data were extracted from the LHS central data warehouse, encompassing diagnoses and medication purchases through December 31, 2024. Structured query language (SQL) and Python scripts were used to automate data retrieval. Socioeconomic status (SES) was determined based on geocoded residential addresses and classified on a 1-20 scale using the Points Location Intelligence® database, which correlates strongly with official national SES indicators.

Using sex-specific longevity thresholds derived from median life expectancy in our health system—84 years for females and 77 years for males—we constructed two groups of eligible individuals: a high-longevity group, comprising individuals who exceeded the cutoff and were alive at follow-up, and a below-average longevity group, comprising individuals who died before reaching the

respective cutoff age. For each individual who died before the threshold, we matched a control with above-average longevity based on sex, birth year, socioeconomic status (SES) group, and year of enrollment in LHS. Matching prioritized individuals with the closest birth dates, ensuring each control was matched to a single case. The index date was defined as the ambulatory visit occurring ten years after the first available EHR record for each individual.

Analysis A: Systemic Screen Procedure

This stage was designed as a hypothesis-generating systematic screen. We compared the exposure rates for all medications dispensed within our health system during the decade preceding the index date. Medications were identified according to their Anatomical Therapeutic Chemical (ATC) classification. For each ATC class, exposure rates were compared between the above-average and below-average longevity groups using Fisher's exact test, with the false discovery rate (FDR) procedure applied to correct for multiple testing. After FDR correction at a 5% threshold, only two medications—both antiprotozoal agents, atovaquone-proguanil (A-P) and mefloquine—remained significantly associated with increased longevity (Supplementary Table 1).

Analysis B: Validation-Exploration Cohort of LHS Patients Exposed to Antiprotozoals

To validate the observed association with reduced mortality and to explore which disease reductions might underlie this effect, we constructed a cohort of individuals aged 40 to 85 who had received at least one prescription for atovaquone-proguanil (A-P) or mefloquine. Each exposed individual was matched to 20 control patients of the same sex, age, socioeconomic status (SES) group, and year of first LHS membership, with priority given to controls with the closest birth dates. The index date was defined as the first recorded exposure to the respective medication for the case group and was assigned to the matched controls.

We compared all-cause mortality and the incidence of a predefined set of age-related conditions between exposed and control groups. Outcomes were analyzed using Kaplan-Meier estimators and Cox

proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals. Follow-up was censored at the date of death or the last recorded medical encounter for individuals who remained alive. For each outcome, individuals with a documented diagnosis prior to the index date were excluded from the corresponding analysis.

Analysis C: TriNetX Validation Cohort

To validate the mortality reduction observed in LHS and to test whether similar disease associations could be reproduced in an independent U.S. population, we conducted analyses using TriNetX, a federated research network comprising electronic health record (EHR) data from 69 healthcare organizations and covering more than 120 million patients.

Validation cohorts included individuals aged 70 to 89 years who had at least one ambulatory visit, which served as the index date. Eligibility required documentation of BMI prior to the index visit to allow for rigorous matching on metabolic status. Cases were defined as individuals with a documented prescription for the medication of interest (atovaquone-proguanil, mefloquine, or nirmatrelvir-ritonavir), while controls were selected from individuals with no record of such use.

Propensity score matching (PSM) was applied to balance groups on age, sex, ethnicity, race, smoking status, diabetes diagnosis, BMI, and HbA1c levels at baseline. Outcomes were compared using Kaplan-Meier survival curves and Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals. Guided by the observed associations in LHS, we evaluated the following outcomes:

- **All-cause mortality**
- **Diabetes** (ICD-10: E08-E13; or incident HbA1c ≥6.5%)
- **Dementia** (F03, G30)
- **Renal insufficiency** (eGFR <45 mL/min/1.73 m²)
- **Hepatic failure** (K72)

- **Congestive heart failure (CHF)** (I50)
- **Myocardial infarction (MI)** (I21)
- **Malignancies**: gastrointestinal (C15-C26), urinary tract (C64-C68), brain (C71), lung (C30-C39)
- **Chronic Obstructive Pulmonary Disease (COPD)** (J43-J44)
- **Hearing loss** (H90-H91)
- **Sjögren's syndrome** (M35.0)
- **Retinal detachment** (H33)
- **Lichen planus** (L43)

Follow-up was censored at the date of the last recorded medical encounter, up to 4000 days (~11 years) after the index date. For each outcome, individuals with a documented diagnosis prior to the index date were excluded from the corresponding analysis.

Data processing in LHS

Data from LHS were extracted from the centralized EHR system and processed using T-SQL queries and Python 3.11 scripts developed by the Leumit Research Institute. To ensure anonymity, all patient identifiers were removed and replaced with study-specific codes prior to analysis. Medication exposure was determined from pharmacy purchase records, covering both prescription and over-the-counter drugs, up to 10 years prior to the index date. Medications were classified according to the Anatomical Therapeutic Chemical (ATC) system.

Statistical analyses

For LHS data, Fisher's exact test was used to compare categorical variables, and two-tailed t-tests were applied for continuous variables. Survival between treatment groups was compared using the log-rank test. All tests were two-tailed, with P-values below 0.05 considered statistically significant. Analyses of LHS data were conducted in R version 4.4.

For TriNetX data, analyses were performed within the TriNetX platform using the built-in "compare outcome" analysis pipeline, which applies Kaplan-Meier estimators and Cox proportional hazards models to propensity score matched cohorts.

Data Availability Statement

The LHS patient-level data generated and analyzed in this study are not publicly available due to patient privacy regulations. Access may be granted to qualified researchers pending approval by the Leumit Health Services Institutional Review Board. Aggregated data supporting the findings of this study are available from the corresponding author upon reasonable request.

TriNetX data are accessible only to licensed member organizations of the TriNetX network, in compliance with HIPAA and institutional guidelines.

Ethics Statement

All LHS data were analyzed retrospectively and in a fully de-identified manner. The study protocol was approved by the Leumit Health Services Institutional Review Board (IRB approval number LEU-0020-24), with a waiver of informed consent.

TriNetX data are de-identified and analyzed under agreements with participating health organizations, compliant with HIPAA and institutional guidelines.

Acknowledgements

Funding

This study was funded internally by Leumit Health Services. ER was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of

Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Conflict of Interest

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

Use of Artificial Intelligence Tools

During manuscript preparation, the authors used ChatGPT (GPT-4o, OpenAI) for language refinement and style editing. The content, data interpretation, and conclusions are entirely the responsibility of the authors, and the AI tool did not contribute to the scientific analyses or results.

References

1. Israel, A. *et al.* Type 2 Diabetes in Patients with G6PD Deficiency. *New England Journal of Medicine* **391**, 568-569 (2024).
2. Israel, A. *et al.* Identification of drugs associated with reduced severity of covid-19 - a case-control study in a large population. *Elife* **10**, (2021).
3. Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *The BMJ* **375**, e067873 (2021).
4. Wang, T. *et al.* Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk. *Nat Med* **30**, 1722-1731 (2024).
5. Afzaal, M. *et al.* Human gut microbiota in health and disease: Unveiling the relationship. *Front Microbiol* **13**, (2022).
6. Sun, J. *et al.* Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation. *NPJ Biofilms Microbiomes* **11**, 43 (2025).

7. Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-analysis. *Parkinsonism Relat Disord* **94**, 1-9 (2022).

8. Zhou, K., Baranova, A., Cao, H., Sun, J. & Zhang, F. Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization. *Schizophrenia* **10**, 75 (2024).

9. Negrini, S. *et al.* Sjögren's syndrome: a systemic autoimmune disease. *Clin Exp Med* **22**, 9-25 (2022).

10. Le Cleach, L. & Chosidow, O. Lichen Planus. *New England Journal of Medicine* **366**, 723-732 (2012).

11. Yang, H.-Y. *et al.* Risk of dementia in patients with toxoplasmosis: a nationwide, population-based cohort study in Taiwan. *Parasit Vectors* **14**, 435 (2021).

12. Sutterland, A. L. *et al.* Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta□analysis. *Acta Psychiatr Scand* **132**, 161-179 (2015).

13. Egorov, A. I. *et al.* Latent Toxoplasma gondii infections are associated with elevated biomarkers of inflammation and vascular injury. *BMC Infect Dis* **21**, 188 (2021).

14. Webster, J. P. The Effect of Toxoplasma gondii on Animal Behavior: Playing Cat and Mouse. *Schizophr Bull* **33**, 752-756 (2007).

15. Vyas, A., Kim, S.-K., Giacomini, N., Boothroyd, J. C. & Sapolsky, R. M. Behavioral changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat odors. *Proceedings of the National Academy of Sciences* **104**, 6442-6447 (2007).

16. Israel, A. *et al.* Atovaquone-proguanil and reduced digestive cancer risk: a *Toxoplasma gondii* connection. *Gut Microbes* **17**, (2025).

17. Leyva, W. H. & Santa Cruz, D. J. Cutaneous toxoplasmosis. *J Am Acad Dermatol* **14**, 600-605 (1986).

18. Soltani, S. *et al.* The Probable Association between Chronic Toxoplasma gondii Infection and Type 1 and Type 2 Diabetes Mellitus: A Case-Control Study. *Interdiscip Perspect Infect Dis* **2021**, 1-6 (2021).

19. Catchpole, A. *et al.* Association between Toxoplasma gondii Infection and Type-1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* **20**, 4436 (2023).

20. Flegr, J. Effects of Toxoplasma on Human Behavior. *Schizophr Bull* **33**, 757-760 (2007).

21. Nayeri, T., Sarvi, S., Sharif, M. & Daryani, A. Toxoplasma gondii: A possible etiologic agent for Alzheimer's disease. *Heliyon* **7**, e07151 (2021).

22. Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update. *Schizophr Bull* **38**, 642-647 (2012).

23. Wang, J. *et al.* Analysis of the Correlation Between Toxoplasma gondii Seropositivity and Alzheimer's Disease. *Pathogens* **13**, 1021 (2024).

24. Wiener, R. C., Waters, C. & Bhandari, R. The association of Toxoplasma gondii IgG and cognitive function scores: NHANES 2013-2014. *Parasitol Int* **78**, 102123 (2020).

25. Israel, A. *et al.* Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced Alzheimer's Disease Risk in Two Cohorts: Implications for a Latent *Toxoplasma gondii* Mechanism. Preprint at https://doi.org/10.1101/2025.03.07.25323566 (2025).

26. Alhusseiny, S. M., Saleh, N. E., El-Zayady, W. M., Hussein, M. S. & El-Beshbishi, S. N. Association between *Toxoplasma gondii* infection and coronary atherosclerosis. *Trans R Soc Trop Med Hyg* **115**, 1190-1197 (2021).

27. Spencer, C. M. & Goa, K. L. Atovaquone. *Drugs* **50**, 176-196 (1995).

28. KOVACS, J. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. *The Lancet* **340**, 637-638 (1992).

29. Secrieru, A., Costa, I. C. C., O'Neill, P. M. & Cristiano, M. L. S. Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis—A Short Bridge between Two Distant Illnesses. *Molecules* **25**, 1574 (2020).

30. El Sharazly, B. M. *et al*. Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. *Acta Trop* **239**, 106810 (2023).

31. Alfonso, Y. & Monzote, L. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. *Open Med Chem J* **5**, 40-50 (2011).

32. Derouin, F. & Santillana-Hayat, M. Anti- *Toxoplasma* Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro. *Antimicrob Agents Chemother* **44**, 2575-2577 (2000).

33. Boyer, K. M. *et al.* Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. *Am J Obstet Gynecol* **192**, 564-571 (2005).

34. Getzmann, S. *et al.* Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span. *Life (Basel)* **14**, (2024).

35. Holland, G. N. Ocular toxoplasmosis: a global reassessment. *Am J Ophthalmol* **136**, 973-988 (2003).

Author contributions:

Conceptualization: AI, EMe, EMa

Methodology: AI, EMe

Investigation: AI, SI, EMe

Writing - original draft: AI

Writing - review & editing: AI, AW, SI, SA, SV, EMa, Eme, ER

Materials & Correspondence: Correspondence and requests for materials should be addressed to AI

Funding: This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Conflict of Interest Statement: The Authors declare that there are no conflicts of interest in relation to the subject of this study.

Abbreviations

A-P: atovaquone-proguanil

BMI: Body Mass Index

BP: Blood pressure

CHF: Congestive Heart Failure

CI: Confidence Interval

CNS: Central nervous system

COPD: Chronic Obstructive Pulmonary Disorder

EHR: Electronic health records

FDR: False Discovery Rate

GI: Gastrointestinal

GFR: Glomerular Filtration Rate

HbA1c: Hemoglobin A1c

HCO: Healthcare organizations

HR: Hazard Ratio

ICD: International Classification of Diseases

LHS: Leumit Health Services

MI: Myocardial Infarction

N-R: nirmatrelvir-ritonavir

OR: Odds Ratio

PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

Table 1. Demographic and clinical characteristics of the LHS exploratory longevity cohort (Analysis A).

A. at the index date

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Gender	Female	7,617 (50.8 %)	7,617 (50.8 %)	1.000	1	
	Male	7,369 (49.2 %)	7,369 (49.2 %)	1.000	1	
Age (years)		70.9 ± 5.9	71.0 ± 5.9	0.098		-0.019
Age category	**60-69**	6,311 (42.11 %)	6,244 (41.67 %)	0.433	1.02 [0.97 to 1.07]	
	70-79	7,303 (48.73 %)	7,317 (48.83 %)	0.881	1.00 [0.95 to 1.04]	
	80-89	1,372 (9.16 %)	1,425 (9.51 %)	0.293	0.96 [0.89 to 1.04]	
Weight (kg)		77.5 ± 17.7	76.3 ± 14.6	<0.001		0.076
Height (cm)		165 ± 10	164 ± 10	0.030		0.030
Body Mass Index (kg/m2)		29.1 ± 6.0	28.5 ± 4.8	<0.001		0.127
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	6,705 (73.6 %)	12,067 (84.3 %)	<0.001	0.52 [0.49 to 0.55]	
	Past smoker	485 (5.32 %)	562 (3.93 %)	<0.001	1.38 [1.21 to 1.56]	
	Smoker	1,919 (21.1 %)	1,684 (11.8 %)	<0.001	2.00 [1.86 to 2.15]	
Socio-economic status (1-20)		9.50 ± 3.14	9.55 ± 3.17	0.266		

B. at the end of follow-up

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Age (years)		74.3 ± 5.7	83.6 ± 6.5	<0.001		-1.213
Age category	**50-59**	7 (0.047 %)		0.016	Inf [1.44 to Inf]	
	60-69	3,051 (20.4 %)		<0.001	Inf [1050.26 to Inf]	
	70-79	8,529 (56.9 %)	4,639 (31.0 %)	<0.001	2.95 [2.81 to 3.09]	
	80-89	3,399 (22.7 %)	7,516 (50.2 %)	<0.001	0.29 [0.28 to 0.31]	
	90-		2,831 (18.9 %)	<0.001	0.00 [0.00 to 0.00]	
died during period		14,986 (100 %)		<0.001	Inf [8402.05 to Inf]	

Panel A shows baseline demographic and clinical characteristics at the index date, comparing individuals who died before reaching the sex-specific median life expectancy (cases) with matched individuals who survived beyond it (controls). Panel B shows the same characteristics at the end of follow-up.
Continuous variables are presented as mean ± standard deviation (SD), with p-values from two-tailed t-tests. Categorical variables are shown as counts and percentages, with p-values from Fisher's exact tests. Odds ratios (OR) with 95% confidence intervals (CI) represent associations with case status. Standardized mean differences (SMD; Cohen's d) are provided as measures of effect size.

Table 2. Demographic and clinical characteristics of the LHS cohort of individuals treated with atovaquone-proguanil or mefloquine versus matched controls (Analysis B).

		Case N=3,876	Control N=77,820	P-value	Odds Ratio	SMD
Gender	Female	2,028 (52.3 %)	40,560 (52.3 %)	1.000	1	
	Male	1,848 (47.7 %)	36,960 (47.7 %)	1.000	1	
Age (years)		56.3 ± 9.4	56.3 ± 9.6	0.990	1.02 [0.95 to 1.10]	0.000
Age category	**40-49**	1,100 (28.4 %)	21,624 (27.9 %)	0.509	0.92 [0.86 to 0.99]	
	50-59	1,325 (34.2 %)	27,903 (36.0 %)	0.023	1.11 [1.03 to 1.19]	
	60-69	1,111 (28.7 %)	20,594 (26.6 %)	0.004	1.02 [0.91 to 1.15]	
	70-79	326 (8.41 %)	6,389 (8.24 %)	0.697	0.27 [0.15 to 0.46]	
	80-89	14 (0.36 %)	1,010 (1.30 %)	<0.001	1.02 [0.95 to 1.10]	
Weight (kg)		76.3 ± 15.3	77.3 ± 16.5	<0.001		-0.060
Height (cm)		168 ± 9	167 ± 10	<0.001		0.079
Body Mass Index (kg/m2)		27.0 ± 4.5	27.5 ± 5.2	<0.001		-0.114
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	3,168 (82.8 %)	56,248 (75.3 %)	<0.001	1.58 [1.45 to 1.73]	
	Past smoker	105 (2.74 %)	2,181 (2.92 %)	0.587	0.94 [0.76 to 1.15]	
	Smoker	553 (14.5 %)	16,301 (21.8 %)	<0.001	0.61 [0.55 to 0.66]	
Ethnic group		88 (2.27 %)	1,760 (2.27 %)	1.000	1	
		3,591 (92.7 %)	71,820 (92.7 %)	1.000	1	
		197 (5.1 %)	3,940 (5.1 %)	1.000	1	

Baseline demographic and clinical characteristics of Leumit Health Services (LHS) patients exposed to atovaquone-proguanil or mefloquine (cases) compared with matched controls. Matching was performed on birth year, sex, ethnic group, and socioeconomic status (SES) category. Reported values reflect characteristics at the index date (first prescription for cases; assigned index date for controls).
Counts and percentages represent the distribution of categorical variables in cases and controls at baseline. Odds ratios (OR) with 95% confidence intervals (CI) are shown for categorical comparisons, alongside p-values from Fisher's exact test. Continuous variables are presented as mean ± standard deviation (SD), with standardized mean differences (SMD; Cohen's d) provided as effect size estimates.
Abbreviations: BP, blood pressure; BMI, body mass index.

Table 3. Demographic and clinical characteristics of the matched TriNetX cohorts for atovaquone-proguanil, mefloquine, and nirmatrelvir-ritonavir exposure (Analysis C).

		Atovaquone-proguanil	Mefloquine	Nirmatrelvir-ritonavir
N		24,498 / 24,498	3,400 / 3,400	124,681 / 124,681
Age at Index		69.0±5.8 / 69.0±5.9	67.6±6.2 / 67.7±6.3	74.9±5.2 / 75.0±5.5
Sex	Female	55.0% / 55.0%	52.0% / 52.5%	57.7% / 58.1%
	Male	45.0% / 45.0%	48.0% / 47.5%	42.3% / 41.9%
Race/Ethnicity	White	82.8% / 83.3%	55.4% / 56.2%	86.7% / 83.5%
	Black or African American	5.3% / 5.2%	15.7% / 15.4%	4.7% / 4.8%
	Hispanic or Latino	1.2% / 1.1%	1.3% / 1.0%	2.8% / 2.7%
	Not Hispanic or Latino	83.8% / 79.7%	82.5% / 78.0%	73.1% / 75.7%
	Asian	4.5% / 4.2%	13.4% / 13.3%	3.4% / 4.1%
	Other Race	1.6% / 1.8%	4.4% / 3.5%	1.9% / 2.5%
Nicotine dependence		3.5% / 3.3%	3.1% / 2.7%	7.9% / 7.5%
Diabetes mellitus		14.0% / 13.6%	22.3% / 21.9%	26.0% / 25.4%
Overweight or obesity (diagnosis)		14.4% / 14.3%	13.0% / 13.4%	26.8% / 25.6%
Hemoglobin A1c (%)		5.9±0.9 / 5.9±1.1	6.3±1.1 / 6.2±1.2	6.0±1.0 / 6.0±1.0
Hemoglobin A1c range	0-5.7 %	25.6% / 25.4%	15.9% / 15.7%	35.9% / 33.7%
	5.7-6.5 %	25.5% / 24.9%	27.1% / 26.5%	38.7% / 35.2%
BMI (kg/m^2)		26.8±4.8 / 26.8±4.9	27.4±4.9 / 27.2±5.1	28.2±5.9 / 28.2±5.8
BMI ranges (kg/m^2)	0-25	52.1% / 52.5%	46.4% / 47.0%	45.7% / 48.6%
	25-30	57.9% / 57.7%	57.4% / 57.8%	60.7% / 61.6%
	30-35	27.9% / 27.9%	30.5% / 30.1%	39.9% / 39.9%
	35-40	9.4% / 9.1%	10.0% / 9.4%	18.6% / 17.9%
	40-	3.4% / 3.2%	4.2% / 3.8%	8.7% / 8.6%

Baseline demographic and clinical characteristics of patients exposed to atovaquone-proguanil, mefloquine, or nirmatrelvir-ritonavir and their propensity score-matched controls in the TriNetX network. Matching was performed on age, sex, race, ethnicity, smoking status, diabetes diagnosis, BMI, and HbA1c levels at baseline. Reported values reflect characteristics at the index date (first prescription for exposed patients; matched ambulatory visit for controls).
Values are presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. For each variable, values before the slash correspond to the medication-exposed group and values after the slash correspond to the matched control group. Variables include demographics, comorbidities, and metabolic parameters relevant to baseline risk stratification across the three exposure cohorts.

Figure 1. Design of the analyses performed to identify and validate medications associated with increased longevity and decreased age-related morbidity.

Analysis A (Discovery, LHS): An exploratory case-control screen was conducted in Leumit Health Services (LHS) to identify medications associated with longevity. Cases were individuals who died before, and controls those who survived beyond, the sex-specific median life expectancy, and were still alive at the time of data extraction. Medication use during the 10 years preceding the index date was compared. Atovaquone-proguanil and mefloquine emerged as candidate drugs associated with increased longevity. Odds ratios (ORs) are reported for this analysis.

Analysis B (Validation-exploration, LHS): A matched 1:20 cohort was assembled in LHS to validate the mortality association and to explore effects on disease incidence. First users of atovaquone-proguanil or mefloquine were matched to controls on age, gender, ethnicity and socioeconomic status and mortality and disease incidence compared during the decade following drug exposure. Cox survival analyses confirmed reduced mortality among exposed patients (HR 0.40 [0.34-0.47], $p < 10^{-3}$). Exploratory analyses of morbidity showed decreased incidence of several age-related conditions (including dementia, diabetes, heart failure, myocardial infarction, COPD, GI and lung cancer), but increased incidence of hearing loss, Sjögren's disease, and lichen planus. Hazard ratios (HRs) are reported for each outcome (Figures 2 and 3).

Analysis C (External validation, TriNetX): Independent replication was performed across US health systems in the TriNetX network. Three large matched cohorts were constructed: two for antiprotozoal drugs prescribed for travel prophylaxis (atovaquone-proguanil and mefloquine) and one for an antiviral used in older or comorbid patients at risk for severe COVID-19 (nirmatrelvir-ritonavir), which also has documented antiprotozoal activity. Mortality was consistently reduced (HR range 0.26-0.50), and disease-specific outcomes showed directionally concordant effects to those observed in LHS, supporting robustness across independent populations and drug classes (Figure 4).


Analysis A: Discovery
Exploratory analysis to identify medications associated with increased longevity (LHS).
Case-control design: compared medication use in the 10 years preceding the index date between individuals who died before vs. those who survived beyond the sex-specific median life expectancy.
Cases
Died early
N=14,986
age: 70.9±5.9
Controls
Still living
N=14,986
age: 71.0±5.9
Two antiprotozoal medications were found to be associated with increased longevity:
Mefloquine
OR 0.32
95% CI [0.15-0.65]
FDR = 0.0001
Atovaquone-Proguanil (A-P)
OR 0.43
95% CI [0.27-0.69]
FDR = 0.0002
Analysis B: Validation-exploration
Matched 1:20 cohort, designed to validate decreased mortality (validation) and to explore disease incidence (exploration).
Cox survival analyses of first users of mefloquine or atovaquone–proguanil (A-P) vs. 20:1 matched controls.
Exposed
Mefloquine or A-P treated
N=3,876
age: 56.3±9.6
Controls
Matched to cases
N=77,820
age: 56.3±9.6
Mortality:
HR 0.40
95% CI [0.34 – 0.47]
p<10^-308
Decreased incidence:
Dementia, HR 0.52
Diabetes: HR 0.83
Heart Failure: HR 0.76
Myocardial Infarct.: HR 0.78
Hepatic failure: HR 0.64
COPD: HR 0.73
GI malignancy: HR 0.70
Lung cancer: HR 0.52
Increased incidence:
Hearing loss: HR 1.25
Sjogren's dis.: HR 1.25
Lichen planus: HR 1.54
Analysis C: External validation
Independent replication in US TriNetX cohorts.
Cox survival analyses were conducted in three cohorts matched for demographic and clinical characteristics: two for drugs prescribed primarily for travel prophylaxis (A-P and mefloquine), and one for an antiviral prescribed to older or comorbid patients at high risk for severe COVID-19 (nirmatrelvir–ritonavir), which also has documented antiprotozoal activity.
A-P treated
vs. matched controls
N=24,498 vs 24,498
age: 69.0±5.8/69.0±5.9
Mortality: HR 0.26
95% CI [0.24 – 0.28]
p<10^-308
Consistent direction of effects for disease incidence (for both decreased and increased outcomes)
Mefloquine treated
vs. matched controls
N=3,400 vs 3,400
age: 67.6±6.2/67.7±6.3
Mortality: HR 0.33
95% CI [0.27 – 0.40]
p<10^-35
Consistent direction of effects for disease incidence
Nirmatrelvir-ritonavir treated
vs. matched controls
N=124,681 vs 124,681,
age: 74.9±5.2/75.0±5.5
Mortality: HR 0.50
95% CI [0.48 – 0.52]
p<10^-308
Consistent direction of effects for disease incidence

Figure 2. Cumulative mortality and incidence of major health outcomes in patients treated with antiprotozoals versus matched controls in LHS (Analysis B).

Kaplan-Meier curves showing cumulative incidence of major health outcomes among Leumit Health Services (LHS) patients exposed to mefloquine or atovaquone-proguanil (red) compared with matched controls (blue). Hazard ratios (HR), 95% confidence intervals (CI), and p-values were estimated from Cox proportional hazards models. Follow-up was censored at the date of death or last recorded visit, whichever occurred later, and individuals with a diagnosis of the outcome prior to the index date were excluded. Shaded areas represent 95% CI.
Panel labels: A, all-cause mortality; B, dementia; C, diabetes mellitus; D, congestive heart failure (CHF); E, myocardial infarction; F, hepatic failure; G, chronic obstructive pulmonary disease (COPD); H, gastrointestinal (GI) malignancy; I, lung malignancy; J, hearing loss; K, dry eye; L, lichen planus.


A Mortality
Control
Atovaquone/proguanil or Mefloquine
HR = 0.40
CI [0.34 to 0.47]
p < 10^-308
cumulative mortality
Time (years)
LHS Numbers at risk
Control 76,166 72,376 66,951 55,447 37,913 23,149
atovaq. 3,876 3,867 3,676 3,101 2,135 1,286
B Dementia
HR = 0.52
CI [0.41 to 0.67]
p < 10^-7
Dementia cumul. incidence
Control 75,594 71,632 66,007 54,462 37,105 22,509
atovaq. 3,871 3,859 3,654 3,070 2,105 1,262
C Diabetes
HR = 0.83
CI [0.75 to 0.92]
p = 0.0006
Diabetes cumul. incidence
Control 61,827 57,064 51,266 41,155 27,397 16,272
atovaq. 3,263 3,188 2,943 2,431 1,657 957
D CHF
HR = 0.76
CI [0.63 to 0.91]
p = 0.003
Heart Failure cumul. incidence
Control 74,852 70,843 65,164 53,688 36,494 22,185
atovaq. 3,847 3,821 3,617 3,038 2,072 1,242
E Myocardial Infarction
HR = 0.78
CI [0.66 to 0.92]
p = 0.003
Myocardial Infarction cumul. incidence
Control 71,543 67,355 61,649 50,458 34,155 20,649
atovaq. 3,659 3,625 3,414 2,860 1,949 1,158
F Hepatic failure
HR = 0.64
CI [0.43 to 0.95]
p = 0.03
Hepatic Failure cumul. incidence
Control 74,945 71,096 65,655 54,318 37,098 22,650
atovaq. 3,838 3,825 3,635 3,062 2,101 1,266
G COPD
HR = 0.73
CI [0.62 to 0.86]
p = 0.0002
COPD cumul. incidence
Control 71,969 67,764 62,085 50,929 34,512 20,918
atovaq. 3,752 3,715 3,496 2,936 1,999 1,193
H GI malignancy
HR = 0.70
CI [0.52 to 0.96]
p = 0.03
GI Malignancy cumul. incidence
Control 75,511 71,606 66,118 54,676 37,310 22,754
atovaq. 3,854 3,838 3,641 3,067 2,108 1,267
I Lung cancer
HR = 0.52
CI [0.33 to 0.82]
p = 0.004
Lung Cancer cumul. incidence
Control 76,000 72,181 66,718 55,209 37,717 23,031
atovaq. 3,872 3,861 3,669 3,093 2,128 1,284
J Hearing loss
Atovaquone/proguanil or Mefloquine
Control
HR = 1.25
CI [1.14 to 1.37]
p < 10^-5
Hearing Loss cumul. incidence
Control 67,585 62,670 56,533 45,557 30,460 18,170
atovaq. 3,405 3,309 3,053 2,482 1,669 979
K Dry eye
HR = 1.25
CI [1.14 to 1.38]
p < 10^-5
Dry Eye cumul. incidence
Control 64,869 59,957 53,978 43,619 29,319 17,613
atovaq. 3,192 3,069 2,810 2,311 1,572 935
L Lichen planus
HR = 1.54
CI [1.03 to 2.31]
p = 0.03
Lichen Planus cumul. incidence
Control 75,643 71,804 66,351 54,916 37,532 22,900
atovaq. 3,830 3,814 3,620 3,049 2,101 1,266

Figure 3. Forest plot of selected health outcomes in patients treated with atovaquone-proguanil or mefloquine vs. matched controls in LHS (Analysis B).

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality and selected age-related conditions among patients treated with mefloquine or atovaquone-proguanil, compared with matched controls in Leumit Health Services (LHS). Outcomes were estimated using Cox proportional hazards models, with follow-up censored at the date of death or last recorded visit, whichever occurred later. Individuals with a diagnosis of the respective condition prior to the index date were excluded. Horizontal bars indicate 95% CIs; values to the left of 1 indicate reduced risk, and those to the right indicate increased risk. Protective associations were identified for mortality, dementia, diabetes, cardiovascular events, hepatic failure, COPD, and several malignancies. Conversely, increased risks were observed for hearing loss, dry eye, and lichen planus.



Figure 4. Cumulative incidence of mortality and age-related health outcomes following antiprotozoal exposure in TriNetX cohorts (Analysis C).

Cumulative incidence curves comparing patients treated with atovaquone-proguanil (left), mefloquine (middle), and nirmatrelvir-ritonavir (right) versus propensity score-matched controls in the TriNetX network. Outcomes include all-cause mortality and selected age-related conditions identified in the LHS cohort, with follow-up extending up to eight years for atovaquone-proguanil and mefloquine and up to three years for nirmatrelvir-ritonavir. Individuals with prior diagnoses of the respective outcomes at baseline were excluded from each analysis. Hazard ratios (HR), 95% confidence intervals (CI), and p-values were estimated using Cox proportional hazards models. Associations included consistent reductions in mortality and morbidity across multiple outcomes, while increased risks were identified for certain adverse events, including hearing loss and ophthalmic conditions.

A Mortality in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,461	20,887	18,557	16,722	15,769	15,056	13,100	10,769	8,720
Control	24,377	16,535	14,399	12,424	10,790	9,301	7,901	6,574	5,430

Mortality in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,389	2,909	2,628	2,389	2,234	2,138	1,950	1,712	1,458
Control	3,380	2,322	2,042	1,774	1,560	1,379	1,203	997	833

Mortality in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	124,324	105,389	90,146	71,911	54,844	31,241	4,775
Control	123,925	92,045	81,597	72,431	64,140	55,673	51,807

B Dementia in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,362	21,311	18,933	17,061	16,089	15,361	13,366	10,987	8,897
Control	24,022	18,666	16,255	14,026	12,181	10,500	8,919	7,421	6,130

Dementia in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,376	2,971	2,684	2,440	2,282	2,184	1,992	1,749	1,489
Control	3,352	2,630	2,313	2,010	1,768	1,563	1,363	1,130	944

Dementia in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	120,390	108,316	92,648	73,907	56,367	32,108	4,907
Control	118,965	98,084	86,950	77,182	68,348	59,326	55,205

C Diabetes in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	21,071	19,832	17,619	15,876	14,972	14,295	12,438	10,224	8,280
Control	21,137	16,815	14,643	12,635	10,973	9,459	8,035	6,685	5,522

Diabetes in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	2,641	2,628	2,374	2,158	2,018	1,932	1,762	1,547	1,317
Control	2,656	2,271	1,997	1,735	1,526	1,349	1,177	975	815

Diabetes in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	92,237	104,527	89,408	71,322	54,395	30,985	4,736
Control	92,948	93,321	82,728	73,435	65,029	56,445	52,525

D A1C > 6.5 in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	22,110	20,585	18,288	16,479	15,541	14,838	12,911	10,613	8,594
Control	22,719	17,865	15,557	13,424	11,658	10,050	8,536	7,103	5,867

A1C > 6.5 in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	2,827	2,780	2,511	2,283	2,135	2,044	1,864	1,636	1,393
Control	3,018	2,415	2,124	1,845	1,623	1,435	1,251	1,037	866

A1C > 6.5 in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	100,468	106,431	91,037	72,622	55,387	31,550	4,822
Control	107,392	95,410	84,579	75,078	66,485	57,709	53,700

E EGFR <45 in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	22,037	18,927	16,816	15,153	14,289	13,643	11,871	9,758	7,902
Control	20,823	15,926	13,868	11,966	10,392	8,958	7,610	6,332	5,230

EGFR <45 in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,060	2,730	2,466	2,242	2,097	2,007	1,830	1,607	1,368
Control	2,832	2,263	1,990	1,729	1,521	1,345	1,173	972	812

EGFR <45 in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	101,347	99,256	84,899	67,726	51,653	29,423	4,497
Control	97,798	88,003	78,013	69,250	61,323	53,228	49,531

F CHF in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,703	20,243	17,984	16,206	15,283	14,591	12,696	10,437	8,451
Control	22,781	17,194	14,973	12,919	11,220	9,672	8,216	6,836	5,646

CHF in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,290	2,816	2,544	2,312	2,163	2,070	1,888	1,657	1,411
Control	3,169	2,415	2,124	1,845	1,623	1,435	1,251	1,037	866

CHF in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	112,435	102,019	87,263	69,611	53,091	30,242	4,622
Control	108,142	92,513	82,012	72,799	64,466	55,957	52,070

G MI in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,956	21,128	18,771	16,914	15,951	15,229	13,251	10,893	8,821
Control	23,479	18,522	16,129	13,917	12,087	10,419	8,850	7,364	6,082

MI in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,313	2,965	2,679	2,435	2,277	2,180	1,988	1,745	1,486
Control	3,262	2,604	2,290	1,989	1,750	1,547	1,349	1,118	934

MI in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	118,040	107,388	91,855	73,274	55,885	31,833	4,865
Control	115,855	98,685	87,482	77,655	68,767	59,689	55,544

H Hepatic failure in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,435	21,826	19,391	17,473	16,478	15,733	13,689	11,253	9,112
Control	24,334	19,611	17,078	14,736	12,798	11,032	9,371	7,797	6,440

Hepatic failure in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,388	3,054	2,759	2,508	2,346	2,245	2,048	1,798	1,531
Control	3,373	2,734	2,404	2,089	1,837	1,624	1,417	1,174	981

Hepatic failure in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	124,313	111,813	95,640	76,293	58,187	33,145	5,066
Control	123,906	102,354	90,735	80,543	71,324	61,909	57,609

I COPD in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,628	20,723	18,410	16,590	15,645	14,937	12,997	10,684	8,652
Control	22,622	17,671	15,388	13,278	11,532	9,940	8,444	7,026	5,803

COPD in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,291	2,886	2,608	2,370	2,217	2,122	1,935	1,699	1,446
Control	3,189	2,508	2,206	1,916	1,686	1,490	1,300	1,077	900

COPD in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	108,807	105,996	90,664	72,325	55,160	31,421	4,802
Control	109,956	95,716	84,850	75,319	66,698	57,893	53,872

J Brain malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,470	21,910	19,465	17,540	16,541	15,793	13,742	11,296	9,147
Control	24,428	19,811	17,252	14,886	12,928	11,144	9,466	7,877	6,506

Brain malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,389	3,067	2,771	2,519	2,355	2,255	2,056	1,805	1,537
Control	3,389	2,775	2,441	2,120	1,865	1,649	1,438	1,192	996

Brain malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	124,453	112,151	95,929	76,524	58,363	33,245	5,081
Control	124,463	102,998	91,306	81,049	71,772	62,298	57,971

K GI malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,127	21,513	19,113	17,222	16,241	15,507	13,493	11,091	8,982
Control	23,936	19,175	16,698	14,408	12,513	10,786	9,162	7,624	6,297

GI malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,363	3,008	2,717	2,470	2,310	2,211	2,016	1,770	1,507
Control	3,319	2,696	2,371	2,060	1,812	1,602	1,397	1,158	967

GI malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	121,705	110,862	94,826	75,645	57,692	32,863	5,023
Control	122,466	101,385	89,876	79,780	70,648	61,323	57,063

L Lung malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,304	21,649	19,233	17,331	16,344	15,605	13,578	11,161	9,038
Control	24,145	19,327	16,830	14,522	12,612	10,872	9,235	7,684	6,347

Lung malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,376	3,033	2,740	2,491	2,330	2,230	2,034	1,785	1,520
Control	3,353	2,712	2,385	2,072	1,823	1,611	1,406	1,165	973

Lung malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	122,459	111,046	94,984	75,770	57,788	32,918	5,031
Control	123,155	101,652	90,113	79,990	70,834	61,484	57,214

M Hearing loss in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	20,096	16,743	14,875	13,403	12,640	12,068	10,501	8,632	6,990
Control	23,102	16,669	14,515	12,525	10,877	9,376	7,965	6,627	5,474

Hearing loss in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	2,940	2,382	2,152	1,956	1,829	1,751	1,597	1,402	1,193
Control	3,239	2,371	2,085	1,811	1,593	1,408	1,229	1,018	851

Hearing loss in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	93,567	96,438	82,488	65,802	50,186	28,587	4,369
Control	114,553	94,425	83,706	74,303	65,798	57,113	53,146

N Dry eye in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,204	21,509	19,109	17,219	16,239	15,504	13,490	11,089	8,980
Control	24,371	19,674	17,132	14,783	12,839	11,067	9,401	7,822	6,461

Dry eye in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,372	2,992	2,703	2,457	2,298	2,200	2,006	1,761	1,499
Control	3,388	2,752	2,420	2,103	1,850	1,635	1,426	1,182	987

Dry eye in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	121,894	111,633	95,486	76,171	58,093	33,092	5,058
Control	123,981	102,732	91,070	80,840	71,587	62,137	57,821

O Retinal tear in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,995	21,539	19,135	17,243	16,261	15,525	13,509	11,105	8,992
Control	24,346	19,676	17,134	14,784	12,840	11,068	9,402	7,823	6,461

Retinal tear in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,336	3,011	2,720	2,473	2,312	2,214	2,019	1,772	1,509
Control	3,382	2,743	2,413	2,096	1,844	1,630	1,422	1,178	984

Retinal tear in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	122,066	111,519	95,389	76,093	58,034	33,058	5,053
Control	123,820	102,757	91,092	80,859	71,604	62,152	57,835

P Lichen planus in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,301	21,757	19,329	17,418	16,425	15,682	13,646	11,217	9,083
Control	24,424	19,773	17,218	14,857	12,903	11,122	9,448	7,861	6,493

Lichen planus in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,376	3,051	2,757	2,505	2,343	2,243	2,046	1,796	1,529
Control	3,389	2,763	2,430	2,111	1,857	1,642	1,432	1,187	991

Lichen planus in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	123,537	111,852	95,673	76,320	58,207	33,157	5,068
Control	124,320	102,926	91,243	80,993	71,722	62,255	57,931